BUND FINANCE

BUND FINANCE › Stocks › AZN

AstraZeneca PLC (AZN)

NYSE · Stock price, chart and technical analysis

US$175.41-3.35 (-1.87%)

Data from Financial Modeling Prep · Nov 19, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$178.76
OpenUS$177.10
Day rangeUS$174.03 – US$178.29
52-week rangeUS$153.41 – US$212.71
Market capUS$272.04B
Volume2.58M
50-day averageUS$170.11
200-day averageUS$180.12
Beta0.21
Last dividend per shareUS$3.23

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$37.4BUS$44.4BUS$45.8BUS$54.1BUS$58.7B
Net incomeUS$112.0MUS$3.3BUS$6.0BUS$7.0BUS$10.3B
EPS (diluted)0.082.113.814.506.54
Gross margin66.8%72.1%82.0%81.1%81.9%
Operating margin2.8%8.5%17.9%18.5%23.4%
Net margin0.3%7.4%13.0%13.0%17.5%
Free cash flowUS$3.8BUS$7.2BUS$6.6BUS$7.3BUS$8.7B
Total debtUS$30.7BUS$29.1BUS$28.6BUS$30.1BUS$29.7B
CashUS$6.3BUS$6.2BUS$5.8BUS$5.5BUS$5.7B

Compound annual growth: revenue 11.9% · net income 209.3% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E25.0x320.6x26.4x
EV / EBITDA13.9x21.9x16.3x
Operating margin23.7%—3.6%
Net margin17.7%—-0.0%
Debt / equity1.32—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About AstraZeneca PLC

SectorHealthcare
IndustryDrug Manufacturers - General
CountryGB
CEOPascal Claude Roland Soriot
Employees96,100
IPO date1993-05-12

AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products lik…

www.astrazeneca.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice